HIMALAYA SINGH

About

Born on January 1st, 1990. I am a dynamic and motivated professional with over 11 years of experience in the scientific research field, specializing in cardiovascular and cancer biology, Vascular Biology, Drug Discovery, Pharmacology and Nanotechnology. I have pursued my doctoral degree from CSIR-CDRI, Lucknow, India in the field of cardiovascular and cancer biology, where I explored the role different gene in regulation of angiogenesis and lymph-angiogenesis during inflammatory disease condition like myocardial infarction and cardiac hypertrophy.
Potential abilities to lead projects and team building capabilities. Actively involved in drug discovery program which involved screening of several bioactive molecules from synthetic and natural origin using various in-vitro and in-vivo assays and other molecular techniques to check their potent antiangiogenic or pro-angiogenic activities and if found potent antiangiogenic agent then it is taken further to check their anti-cancer activity using orthotopic xenograft murine model.
Committed to fostering a collaborative work environment and maintain high standards of integrity and professionalism. Seeking to leverage expertise and passion for research and development and to motivate future generation to be an active part of research arenas to contribute to the success of a forward-thinking generation.

Employment

• University of Lucknow DBT-Research Associate II
  2025 - 2026
• University of Lucknow DBT-Research Associate
  2024 - 2025
• Indian Institute of Toxicology Research Senior Project Associate I
  2023 - 2024
• Central Drug Research Institute Project Assistant
  2014 - 2016

Education

• Central Drug Research Institute Doctorate of Philosophy (PhD)
  2016 - 2023
• Jamia Hamdard Master of Science (MSc)
  2011 - 2013
• University of Lucknow Bachelor of Science (BSc)
  2008 - 2011

Projects & Funding

Projects & funding information is unavailable.

Publications (11)

• Functionalized azirine based scaffolds as endothelin inhibitors for the selective anti-angiogenic activity
  European Journal of Medicinal Chemistry 2024 DOI: 10.1016/j.ejmech.2024.116510
  +Save
• Androsin alleviates non-alcoholic fatty liver disease by activating autophagy and attenuating de novo lipogenesis
  Phytomedicine 2024 DOI: 10.1016/j.phymed.2024.155702
  +Save
• Inhibition of poly (ADP-ribose) Polymerase-1 (PARP-1) improves endothelial function in pulmonary hypertension
  Pulmonary Pharmacology & Therapeutics 2023 DOI: 10.1016/j.pupt.2023.102200
  +Save
• Nitric Oxide: From Research to Therapeutics
  Springer International Publishing 2023 DOI: 10.1007/978-3-031-24778-1
  +Save
• 2,3-Difunctionalized Benzo[b]thiophene Scaffolds Possessing Potent Antiangiogenic Properties
  Journal of Medicinal Chemistry 2022 DOI: 10.1021/acs.jmedchem.1c00892
  +Save
• Involvement of mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK2) in endothelial dysfunction associated with pulmonary hypertension
  Life Sciences 2021 DOI: 10.1016/j.lfs.2021.120075
  +Save
• Synthesis and Evaluation of a Zinc Eluting rGO/Hydroxyapatite Nanocomposite Optimized for Bone Augmentation
  ACS Biomaterials Science & Engineering 2020 DOI: 10.1021/acsbiomaterials.0c00370
  +Save
• Autophagy inhibition by chloroquine prevents increase in blood pressure and preserves endothelial functions
  Tropical Journal of Pharmaceutical Research 2020 DOI: 10.4314/tjpr.v19i4.16
  +Save
• Reversal of Osteopenia in Ovariectomized Rats by Pentoxifylline: Evidence of Osteogenic and Osteo-Angiogenic Roles of the Drug
  Calcified Tissue International 2019 DOI: 10.1007/s00223-019-00567-4
  +Save
• Fatty acid synthase modulates proliferation, metabolic functions and angiogenesis in hypoxic pulmonary artery endothelial cells
  European Journal of Pharmacology 2017 DOI: 10.1016/j.ejphar.2017.09.042
  +Save